HDL Apomics:

HDL Apomics is looking at a new way to measure and develop pharmaceutical treatments in the cardiovascular theropeutic area by analyzing HDL.

  • Technology Presenter: Scott Altmann
  • Accelerator-Commercial Catalyst: Caroline Hoedemaker, VALUEDsolutions
  • Defined Milestone: Prepare for fall Commercial Presentations to the Pharmaceutical Industry
  • Targeted Completion: 1 months